A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer

Alain Thibault, William D. Figg, Raymond Bergan, Richard M. Lush, Charles E. Myers, Anne Tompkins, Eddie Reed, Dvorit Samid

Research output: Contribution to journalArticle

114 Citations (Scopus)

Abstract

Aims and Background: Decitabine (5-aza-2'-deoxycytidine) is an S-phase- specific pyrimidine analog with hypomethylation properties. In laboratory models of prostate cancer (PC-3 and DU-145), decitabine induces cellular differentiation and enhanced expression of genes involved in tumor suppression, immunogenicity, and programmed cell death. Methods: We conducted a phase II study of decitabine in 14 men with progressive, metastatic prostate cancer recurrent after total androgen blockade and flutamide withdrawal. Decitabine was administered at a dose of 75 mg/m2/dose IV as a I hour infusion every 8 hours for three doses. Cycles of therapy were repeated every 5 to 8 weeks to allow for resolution of toxicity. Results: Two of 12 patients evaluable for response had stable disease with time to progression of more than 10 weeks. This activity was seen in 2 of 3 African-American patients. Toxicity was similar to previously reported experience. No significant changes in urinary concentrations of the angiogenic factor bFGF, a potential biomarker of tumor activity, were identified over time in 7 unselected patients with progressive disease. Conclusions: We conclude that decitabine is a well tolerated regimen with modest clinical activity against hormone-independent prostate cancer. Further investigations in patients of African-American origin may be warranted.

Original languageEnglish (US)
Pages (from-to)87-89
Number of pages3
JournalTumori
Volume84
Issue number1
StatePublished - Jan 1998
Externally publishedYes

Fingerprint

decitabine
Prostatic Neoplasms
Hormones
African Americans
Flutamide
Angiogenesis Inducing Agents
Tumor Biomarkers
S Phase
Androgens
Cell Death

Keywords

  • Angiogenesis
  • bFGF
  • Chemotherapy
  • Malignancy
  • Tumor biology
  • Tumor markers

ASJC Scopus subject areas

  • Cancer Research

Cite this

Thibault, A., Figg, W. D., Bergan, R., Lush, R. M., Myers, C. E., Tompkins, A., ... Samid, D. (1998). A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori, 84(1), 87-89.

A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. / Thibault, Alain; Figg, William D.; Bergan, Raymond; Lush, Richard M.; Myers, Charles E.; Tompkins, Anne; Reed, Eddie; Samid, Dvorit.

In: Tumori, Vol. 84, No. 1, 01.1998, p. 87-89.

Research output: Contribution to journalArticle

Thibault, A, Figg, WD, Bergan, R, Lush, RM, Myers, CE, Tompkins, A, Reed, E & Samid, D 1998, 'A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer', Tumori, vol. 84, no. 1, pp. 87-89.
Thibault, Alain ; Figg, William D. ; Bergan, Raymond ; Lush, Richard M. ; Myers, Charles E. ; Tompkins, Anne ; Reed, Eddie ; Samid, Dvorit. / A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. In: Tumori. 1998 ; Vol. 84, No. 1. pp. 87-89.
@article{c1d4fdf702494d0b975eae8307f0c5f2,
title = "A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer",
abstract = "Aims and Background: Decitabine (5-aza-2'-deoxycytidine) is an S-phase- specific pyrimidine analog with hypomethylation properties. In laboratory models of prostate cancer (PC-3 and DU-145), decitabine induces cellular differentiation and enhanced expression of genes involved in tumor suppression, immunogenicity, and programmed cell death. Methods: We conducted a phase II study of decitabine in 14 men with progressive, metastatic prostate cancer recurrent after total androgen blockade and flutamide withdrawal. Decitabine was administered at a dose of 75 mg/m2/dose IV as a I hour infusion every 8 hours for three doses. Cycles of therapy were repeated every 5 to 8 weeks to allow for resolution of toxicity. Results: Two of 12 patients evaluable for response had stable disease with time to progression of more than 10 weeks. This activity was seen in 2 of 3 African-American patients. Toxicity was similar to previously reported experience. No significant changes in urinary concentrations of the angiogenic factor bFGF, a potential biomarker of tumor activity, were identified over time in 7 unselected patients with progressive disease. Conclusions: We conclude that decitabine is a well tolerated regimen with modest clinical activity against hormone-independent prostate cancer. Further investigations in patients of African-American origin may be warranted.",
keywords = "Angiogenesis, bFGF, Chemotherapy, Malignancy, Tumor biology, Tumor markers",
author = "Alain Thibault and Figg, {William D.} and Raymond Bergan and Lush, {Richard M.} and Myers, {Charles E.} and Anne Tompkins and Eddie Reed and Dvorit Samid",
year = "1998",
month = "1",
language = "English (US)",
volume = "84",
pages = "87--89",
journal = "Tumori",
issn = "0300-8916",
publisher = "Wichtig Publishing",
number = "1",

}

TY - JOUR

T1 - A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer

AU - Thibault, Alain

AU - Figg, William D.

AU - Bergan, Raymond

AU - Lush, Richard M.

AU - Myers, Charles E.

AU - Tompkins, Anne

AU - Reed, Eddie

AU - Samid, Dvorit

PY - 1998/1

Y1 - 1998/1

N2 - Aims and Background: Decitabine (5-aza-2'-deoxycytidine) is an S-phase- specific pyrimidine analog with hypomethylation properties. In laboratory models of prostate cancer (PC-3 and DU-145), decitabine induces cellular differentiation and enhanced expression of genes involved in tumor suppression, immunogenicity, and programmed cell death. Methods: We conducted a phase II study of decitabine in 14 men with progressive, metastatic prostate cancer recurrent after total androgen blockade and flutamide withdrawal. Decitabine was administered at a dose of 75 mg/m2/dose IV as a I hour infusion every 8 hours for three doses. Cycles of therapy were repeated every 5 to 8 weeks to allow for resolution of toxicity. Results: Two of 12 patients evaluable for response had stable disease with time to progression of more than 10 weeks. This activity was seen in 2 of 3 African-American patients. Toxicity was similar to previously reported experience. No significant changes in urinary concentrations of the angiogenic factor bFGF, a potential biomarker of tumor activity, were identified over time in 7 unselected patients with progressive disease. Conclusions: We conclude that decitabine is a well tolerated regimen with modest clinical activity against hormone-independent prostate cancer. Further investigations in patients of African-American origin may be warranted.

AB - Aims and Background: Decitabine (5-aza-2'-deoxycytidine) is an S-phase- specific pyrimidine analog with hypomethylation properties. In laboratory models of prostate cancer (PC-3 and DU-145), decitabine induces cellular differentiation and enhanced expression of genes involved in tumor suppression, immunogenicity, and programmed cell death. Methods: We conducted a phase II study of decitabine in 14 men with progressive, metastatic prostate cancer recurrent after total androgen blockade and flutamide withdrawal. Decitabine was administered at a dose of 75 mg/m2/dose IV as a I hour infusion every 8 hours for three doses. Cycles of therapy were repeated every 5 to 8 weeks to allow for resolution of toxicity. Results: Two of 12 patients evaluable for response had stable disease with time to progression of more than 10 weeks. This activity was seen in 2 of 3 African-American patients. Toxicity was similar to previously reported experience. No significant changes in urinary concentrations of the angiogenic factor bFGF, a potential biomarker of tumor activity, were identified over time in 7 unselected patients with progressive disease. Conclusions: We conclude that decitabine is a well tolerated regimen with modest clinical activity against hormone-independent prostate cancer. Further investigations in patients of African-American origin may be warranted.

KW - Angiogenesis

KW - bFGF

KW - Chemotherapy

KW - Malignancy

KW - Tumor biology

KW - Tumor markers

UR - http://www.scopus.com/inward/record.url?scp=0031945210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031945210&partnerID=8YFLogxK

M3 - Article

VL - 84

SP - 87

EP - 89

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 1

ER -